by Strattmont Group | Nov 6, 2019 | Events, News
An anti-carcinoma monoclonal antibody (mAb) NEO-201 can also target and eliminate human immunosuppressive regulatory T cells (Tregs) Authors: Philip M. Arlen, MD; Kwong Y. Tsang, PhD; Massimo Fantini, PhD; Justin M. David; M Maria Morelli, MD; Christina M. Annunzata,...
by Strattmont Group | Oct 15, 2019 | Events, News
Philip M. Arlen, M.D.Summary: Target is broadly expressed in multiple solid tumors.Exhibits both ADCC and CDC killing.Promising pre-clinical results with complete regression of tumor in animal models.GMP manufacturing completed.Pre-clinical testing showed that NEO-201...
by jhollister | Nov 1, 2018 | Home Page, News
Clinical trial tests safety and dosing of NEO-201 antibody in patients with advanced cancer NIH 11/01/2018 Patients with advanced solid tumors may be eligible to participate in a new clinical trial at the NIH Clinical Center. Read Full Article Click...
by jhollister | Jan 8, 2018 | News
Preclinical Characterization of a Novel Monoclonal Antibody NEO-201 for the Treatment of Human Carcinomas View the Publication Click...
by Jen Hodson | Apr 2, 2017 | Home Page, News
Rockville, MD, April 2, 2017 – Precision-Biologics Inc. today announced an abstract reporting data on the company’s neo-antigen program has been accepted for an oral presentation at the upcoming 110th Annual Meeting of the American Association of...
by Jen Hodson | Nov 21, 2016 | Home Page, News, Presentations
Embed from Getty Images Clinical investigators from Moffitt and Walter Reed Army Institute present data of first Phase II Neoepitope Antibody Immunotherapy Clinical Trial completed at John’s Hopkins, Duke and Moffitt as a potential new immunotherapy treatment for...
